CN110699271A - Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation - Google Patents
Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation Download PDFInfo
- Publication number
- CN110699271A CN110699271A CN201810751933.2A CN201810751933A CN110699271A CN 110699271 A CN110699271 A CN 110699271A CN 201810751933 A CN201810751933 A CN 201810751933A CN 110699271 A CN110699271 A CN 110699271A
- Authority
- CN
- China
- Prior art keywords
- cqpc02
- fsm
- lactobacillus plantarum
- constipation
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 42
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 41
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 41
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 41
- 235000013305 food Nutrition 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 9
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 244000068988 Glycine max Species 0.000 claims description 18
- 235000010469 Glycine max Nutrition 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 235000013322 soy milk Nutrition 0.000 claims description 17
- 235000013336 milk Nutrition 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 235000019985 fermented beverage Nutrition 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 description 42
- 210000000813 small intestine Anatomy 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 33
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 15
- 101800002372 Motilin Proteins 0.000 description 15
- 102400001357 Motilin Human genes 0.000 description 15
- 235000021110 pickles Nutrition 0.000 description 15
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 13
- 102000012440 Acetylcholinesterase Human genes 0.000 description 13
- 108010022752 Acetylcholinesterase Proteins 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 13
- 102400000096 Substance P Human genes 0.000 description 13
- 101800003906 Substance P Proteins 0.000 description 13
- 229940022698 acetylcholinesterase Drugs 0.000 description 13
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102000003566 TRPV1 Human genes 0.000 description 12
- 101150016206 Trpv1 gene Proteins 0.000 description 12
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 12
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 12
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 11
- 102100020880 Kit ligand Human genes 0.000 description 10
- 101710177504 Kit ligand Proteins 0.000 description 10
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 10
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 9
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 9
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 9
- 235000008696 isoflavones Nutrition 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000012086 standard solution Substances 0.000 description 9
- 108090000991 Aquaporin 3 Proteins 0.000 description 8
- 102000004363 Aquaporin 3 Human genes 0.000 description 8
- 206010016100 Faeces discoloured Diseases 0.000 description 7
- 239000003833 bile salt Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 235000007240 daidzein Nutrition 0.000 description 7
- 230000005176 gastrointestinal motility Effects 0.000 description 7
- 235000006539 genistein Nutrition 0.000 description 7
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 7
- 229940045109 genistein Drugs 0.000 description 7
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 7
- 235000008466 glycitein Nutrition 0.000 description 7
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 7
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 6
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 6
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 6
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 6
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 description 6
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 102100029406 Aquaporin-7 Human genes 0.000 description 5
- 101000771402 Homo sapiens Aquaporin-7 Proteins 0.000 description 5
- 101000771413 Homo sapiens Aquaporin-9 Proteins 0.000 description 5
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000008855 peristalsis Effects 0.000 description 5
- 235000003687 soy isoflavones Nutrition 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000008991 intestinal motility Effects 0.000 description 3
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 239000003629 gastrointestinal hormone Substances 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000037817 intestinal injury Diseases 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses Lactobacillus plantarum CQPC02 with the preservation number of CGMCC NO.14491 and application thereof in preparing food for improving constipation, which not only expands the application range of the Lactobacillus plantarum CQPC02 and improves the application value thereof, but also brings new hope for improving the constipation.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and relates to lactobacillus plantarum and application thereof in preparation of food.
Background
The production process of Sichuan pickle comprises cleaning fresh pickle, sealing pickle in jar, and anaerobically fermenting soaked pickle in saline water. The pickle water contains abundant natural lactic acid bacteria, and plays a key role in forming the flavor and the quality of the pickle. It uses soluble components (mainly sugar and nitrogen-containing substances) to proliferate, generate acidic substances and metabolize flavor components, so that the pickle has unique sour and crisp taste. The microorganism contained in the pickle water mainly comprises lactobacillus plantarum, L.brevis, lactobacillus casei, fermentation yeast, lactobacillus acidophilus and the like. The difference in the types of lactic acid bacteria may be caused by factors such as regions, climate and production process habits. Certain lactic acid bacteria are also used as probiotics and have various benefits to human health, including improving constipation, colitis, weight loss, etc. In order to better utilize the microbial resources, more extensive separation and identification work should be carried out, abundant strain resources are accumulated, and abundant industrial probiotic species are developed.
Disclosure of Invention
The invention aims to separate and identify microorganisms in pickle water and research the activity and application of the microorganisms.
Through research, the invention provides the following technical scheme:
1. lactobacillus plantarum (Lactobacillus plantarum) CQPC02 with the preservation number of CGMCC NO. 14491.
2. Application of lactobacillus plantarum CQPC02 in preparing food for improving constipation.
Further, the food is a fermented beverage.
Further, the food product is fermented soymilk.
3. A beverage is prepared by fermenting Lactobacillus plantarum CQPC 02.
Further, the beverage is soy milk.
4. A method for preparing soybean milk by fermenting Lactobacillus plantarum CQPC02 comprises the following steps: soaking soybean in water 3 times of the soybean for 12 hr, grinding, filtering, and concentrating to 10%5CFU/mL inoculated with Lactobacillus plantarum CQPC02, fermented at 37 ℃ for 12 hours.
The invention separates and identifies the microorganisms in the pickle water, one of the Lactobacillus plantarum is named as CQPC02, and the Lactobacillus plantarum is preserved in China general microorganism center of microorganism culture preservation management committee (CGMCC for short, address: No.3 Xilu No.1 Beichen of the sunward area in Beijing city) in 8-4 months in 2017, and the preservation number is CGMCC NO. 14491.
The High Performance Liquid Chromatography (HPLC) assay showed that the total content of soy isoflavones in the Lactobacillus plantarum CQPC02 fermented soymilk (LP-CQPC02-FSM) was highest and contained more free glycosides (daidzein, glycitein, genistein) than the unfermented soymilk (U-FSM) and the Lactobacillus bulgaricus fermented soymilk (LB-FSM).
The results of the experiments of LP-CQPC02-FSM on charcoal-induced constipation mice show that: compared with a model group, the LP-CQPC02-FSM can promote intestinal peristalsis, improve the small intestine propulsion rate, shorten the first-grain black stool time, obviously improve the serum MTL (motilin), Gas (gastrin), ET (endothelin), AChE (acetylcholinesterase), SP (substance P) and VIP (vasoactive intestinal peptide) levels of a constipated mouse, obviously reduce the SS (somatostatin) level, increase the mRNA expression of c-Kit, SCF, GDNF and AQP9 in the small intestine of the constipated mouse, reduce the mRNA expression of TRPV1 and AQP3, has a good improvement effect on constipation, and is obviously superior to U-FSM and LB-FSM.
The invention has the beneficial effects that: the invention provides a lactobacillus plantarum CQPC02 which can be used for preparing food for improving constipation, such as fermented beverage (such as fermented soybean milk), can effectively inhibit constipation, has better effect than the commonly used lactobacillus bulgaricus, not only expands the application range of the lactobacillus plantarum CQPC02 and improves the application value thereof, but also brings new hope for improving constipation.
Drawings
FIG. 1 shows the colony morphology of Lactobacillus plantarum CQPC 02.
FIG. 2 shows the gram-stained Lactobacillus plantarum CQPC 02.
FIG. 3 is an agarose gel electrophoresis of the 16S rDNA PCR amplification product of Lactobacillus plantarum CQPC02, wherein M is a DNA molecular weight standard, 0 is a negative control, and 1 is Lactobacillus plantarum CQPC 02.
FIG. 4 is a HPLC method for determining soybean isoflavone content in soybean milk, wherein A is mixed standard solution, B is-FSM), C is LB-FSM, and D is LP-CQPC 02-FSM; the chromatographic peaks No. 1-6 are daidzin, glycitin, genistin, daidzein, glycitein and genistein in sequence.
FIG. 5 shows the first black stool time of the mice,a-eindicating that there is a significant difference (p) between the groups<0.05)。
FIG. 6 is a histopathological section of mouse small intestine.
FIG. 7 shows c-The level of mRNA expression of Kit and SCF,a-eindicating that there is a significant difference (p) between the groups<0.05)。
FIG. 8 is a graph of TRPV1 and GDNF mRNA expression levels in mouse small intestine,a-eindicating that there is a significant difference (p) between the groups<0.05)。
FIG. 9 is a graph showing AQP3 and AQP9mRNA expression levels in mouse small intestine,a-eindicating that there is a significant difference (p) between the groups<0.05)。
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings.
First, the separation and identification of Lactobacillus plantarum CQPC02
1. Experimental Material
The method comprises the steps of collecting 6 parts of pickle water obtained by natural fermentation of farmers in the southern shore area of Chongqing, respectively sucking 40mL of pickle water, putting the pickle water into a sterile centrifuge tube, putting the pickle water into a food sampling box, and storing the pickle water in a laboratory refrigerator at 4 ℃ for later use.
2. Separation and purification of lactic acid bacteria
Respectively taking 1mL of sauerkraut water sample, and performing 10-fold gradient dilution to 10 with sterile physiological saline water-6Then take 10 out-4、10-5、10-6The 3 gradients of bacteria solution 100 u L plate coating, 37 degrees C culture 24-48h, observed and recorded colony morphology. And selecting colonies with different forms on the plate for streaking separation, culturing at 37 ℃ for 48h, then selecting single colonies with different forms on the plate again for streaking separation, and repeating the steps for 2 to 3 times until pure single colonies with consistent forms are obtained.
The colony morphology of the strain CQPC02 is shown in FIG. 1, and the colony is mostly white or milky white, round in shape, neat in edge, and moist and smooth in surface.
3. Preliminary identification of lactic acid bacteria
The pure colonies on the plate were picked and inoculated in 5mL MRS liquid medium and cultured at 37 ℃ for 24 h. And (3) putting 1mL of the culture medium containing the bacteria into a sterile centrifuge tube, centrifuging for 10min at 4000r/min, removing an upper culture medium, suspending the thallus precipitate in sterile normal saline, performing gram stain microscopy, and preliminarily identifying the positive thallus precipitate as the lactobacillus.
The strain with the number of CQPC02 shows positive gram staining, and under 100 times of oil lens, the cell morphology of the strain is shown in figure 2, the cell morphology has long rods and short rods, and no budding is existed.
4. Lactic acid bacteria DNA extraction
Inoculating the purified suspected target strain into MRS broth, culturing at 37 ℃ for 18-24h, and extracting DNA by using a bacterial genome DNA extraction kit. The extracted DNA was stored in a freezer at-20 ℃ for further use.
5. PCR amplification and agarose gel electrophoresis detection of genome DNA
The extracted DNA was used to amplify 16S rDNA by PCR, wherein 1. mu.L of the forward primer 27F (5'-AGAGTTTGATCCTGGCTCAG-3', SEQ ID No.1), 1. mu.L of the reverse primer 1495R (5'-CTACGGCTACCTTGTTACGA-3', SEQ ID No.2), 12.5. mu.L of 2 XTaq plus Buffer, and 1. mu.L of the template DNA were used as the primer2O make up the system to 25. mu.L. And sterile ultrapure water was used as a negative control instead of the template DNA. The amplification conditions were: 5min at 94 ℃; 29 cycles of 94 ℃ for 30s, 55 ℃ for 30s and 72 ℃ for 1 min; finally, extension is carried out for 5min at 72 ℃. Then 5 mul of amplification product is taken to carry out agarose gel electrophoresis detection, the agarose concentration is 1.5%, the electrophoresis condition is 110V, and 45 min.
The agarose gel electrophoresis detection result of the 16S rDNA amplification product of the strain with the number of CQPC02 is shown in figure 3, and a lane of a negative control group has no band, which indicates that the strain is not polluted in the PCR amplification process; the lane of the strain numbered CQPC02 has a band of about 1500bp in length, corresponding to the expected length of the amplified fragment.
The 16S rDNA amplification product of the strain with the serial number of CQPC02 is subjected to sequencing by Beijing Okagaku Biotechnology Co., Ltd, and the sequence is shown as SEQ ID No. 3. The alignment analysis of the sequences using the BLAST (basic Local alignment search tool) program in NCBI revealed that the strain numbered CQPC02 was Lactobacillus plantarum (Lactobacillus plantarum) among lactic acid bacteria, which has 99% homology to known lactic acid bacteria in the Gene Bank database.
6. In vitro resistance screening of lactic acid bacteria
(1) Capacity to tolerate 0.3% bile salts
Adding pig bile salt into MRS-THIO culture medium (MRS broth containing 0.2% sodium thioglycolate) to make its concentration be 0.3%, and sterilizing at 121 deg.C for 15 min; inoculating activated 5mL strain into MRS-THIO culture medium containing no bile salt (0.0%) and MRS-THIO culture medium containing 0.3% bile salt (2% (v/v)), respectively, culturing at 37 deg.C for 24 hr with blank culture medium (MRS-THIO culture medium without inoculated strain), and respectively determining OD of the culture medium with different concentrations600nmThe tolerance of the strain to bile salts was calculated according to equation (1):
the result shows that the survival rate of the strain with the number of CQPC02 in 0.3% of bile salt is 17.3 +/-0.19%, and the strain has stronger bile salt tolerance capability.
(2) Simulated gastric fluid resistance test
Preparing artificial gastric juice: consists of 0.2 percent of NaCl and 0.35 percent of pepsin, the pH value is adjusted to 3.0 by 1mol/L of HCl, and then the mixture is filtered and sterilized by a filter membrane with the pore diameter of 0.22 mu m for standby.
Sucking 5mL of cultured bacteria-containing culture medium in a super-clean workbench, centrifuging for 10min at 3000r/min in a 10mL sterile centrifuge tube, removing an upper layer culture medium, collecting thalli, adding equal volume (5mL) of sterile normal saline, uniformly mixing to prepare a bacterial suspension, then uniformly mixing 1mL of bacterial suspension with 9mL of artificial gastric juice with the pH of 3.0, treating 1mL of the mixed solution as the artificial gastric juice for 0h, and culturing the rest 9mL of the mixed solution in a constant-temperature water bath shaker (37 ℃, 150r/min) for 3 h. The samples of 0h and 3h are respectively diluted by 10 times of gradient, the viable count is determined by selecting proper gradient and adopting a plate coating method, the samples are cultured for 48h at 37 ℃ on an MRS solid culture medium, and the survival rate (%) is calculated according to a formula (2).
The result shows that the survival rate of the strain with the number of CQPC02 in artificial gastric juice with the pH value of 3.0 is 92.06 +/-6.91%, and the strain has stronger gastric acid resistance.
Secondly, lactobacillus plantarum CQPC02 fermented soymilk
Soaking semen glycines (1kg) in water 3 times the weight of semen glycines for 12 hr, grinding into slurry, filtering, and concentrating to 10% respectively5CFU/mL inoculated with Lactobacillus plantarum CQPC02 and Lactobacillus bulgaricus, fermented at 37 deg.C for 12h to obtain Lactobacillus plantarum CQPC02 fermented soybean milk (LP-CQPC02-FSM) and Lactobacillus bulgaricus fermented soybean milk (LB-FSM). Unfermented soymilk (U-FSM) was also used as a control.
Third, HPLC method is used for determining the content of soybean isoflavone in the soymilk
The soybean contains soybean isoflavone substances with intestinal tract benefiting function besides common components such as protein. After fermentation with lactic acid bacteria, the bound soy isoflavones present in the soy milk are converted to free soy isoflavones which are more readily digested and absorbed.
1. Chromatographic conditions
A chromatographic column: pntulis QS-C18 chromatography column (4.6 mm. times.250 mm,5 μm); mobile phase A: acetonitrile; mobile phase B: 0.1% o phosphoric acid; detection wavelength: 254 nm; column temperature: 40 ℃; flow rate: 1 mL/min; sample introduction amount: 10 μ L. The gradient elution mobile phase ratios are shown in table 1.
TABLE 1 gradient elution mobile phase ratio
2. Preparation of Standard solutions
Respectively and precisely weighing 20mg of daidzin, 20mg of glycitin, 20mg of genistin, 20mg of daidzein, 20mg of glycitein and 20mg of genistein in a 20mL volumetric flask, dissolving with 80% methanol and diluting to scale to obtain a single standard stock solution.
Diluting each single standard stock solution by 6, 12, 24, 36 and 48 times respectively to prepare single standard solutions with series concentrations.
1mL of each of 6 single standard stock solutions is taken in a 10mL volumetric flask, and diluted to the scale with 80% methanol to serve as a mixed standard solution.
3. Experiment of system applicability
Precisely absorbing 6 single standard solutions, injecting into a liquid chromatograph, recording chromatogram, and determining retention time of daidzin, glycitin, genistin, daidzein, glycitein, and genistein as 16.899, 18.298, 26.582, 39.483, 41.325, and 48.525 min. And then precisely absorbing the mixed standard solution, injecting the mixed standard solution into a liquid chromatograph, recording a chromatogram (see fig. 4A), determining that the No.1 to No. 6 chromatographic peaks in the chromatogram are daidzin, glycitin, genistin, daidzein, glycitein and genistein in sequence according to retention time and the maximum absorption wavelength displayed by an ultraviolet spectrum, wherein the separation degree between adjacent peaks meets the requirement.
4. Preparation of test solution
Respectively taking U-FSM, LB-FSM and LP-CQPC02-FSM 2mL in a 50mL volumetric flask, adding 80% methanol to the near scale, performing ultrasonic treatment at 50 ℃ for 1h, diluting with 80% methanol to the scale, mixing uniformly, centrifuging at 9000r/min for 15min, taking supernatant, and filtering with a 0.45 mu m filter membrane to obtain a test solution.
5. Drawing of standard curve
Precisely absorbing 5 mu L of single standard solution with a series of concentrations respectively, injecting the single standard solution into a liquid chromatograph, recording a chromatogram, and performing linear regression on the sample amount (X) by using a peak area (Y). The regression equation for the 6 soybean isoflavone standards is shown in table 2.
TABLE 26 regression equation for soy isoflavone standards
6. Measurement of test solution
Precisely absorbing 5 mu L of the test solution, injecting the test solution into a liquid chromatograph, recording a chromatogram, and calculating the content of 6 soybean isoflavones in the soybean milk by using the peak area according to a regression equation listed in a table 2. The chromatograms of U-FSM, LB-FSM and LP-CQPC02-FSM are shown in FIGS. 4B, 4C and 4D, respectively, and it can be seen that U-FSM and LB-FSM contain daidzin, glycitin, genistin, daidzein and genistein, and that LP-CQPC02-FSM contains glycitein in addition to the above five isoflavones. The results of the calculation of the total isoflavone content in U-FSM, LB-FSM and LP-CQPC02-FSM are shown in Table 3, and it can be seen that LP-CQPC02-FSM has the highest total isoflavone content and contains more free glycosides (daidzein, glycitein, genistein) and less bound glycosides (daidzin, glycitin, genistin) compared to U-FSM and LB-FSM. From these results, it was seen that lactobacillus plantarum CQPC02 produced more active soy isoflavones during the fermentation of soy milk than lactobacillus bulgaricus.
TABLE 3 Soy milk isoflavone content (. mu.g/mL)
Fourth, improving effect of lactobacillus plantarum CQPC02 fermented soymilk on constipation model mice
1. Laboratory animal
2. Experimental methods
One week after adaptive feeding of 50 mice, the mice were randomly divided into 5 groups of 10, namely a normal group, a model group, a U-FSM group, an LB-FSM group and an LP-CQPC02-FSM group. The whole experiment period is 9 days, the normal group and the model group are respectively irrigated with normal saline every day, and the U-FSM group, the LB-FSM group and the LP-CQPC02-FSM are irrigated with U-FSM, LB-FSM and LP-CQPC02-FSM for 4 times every day, and the total volume is 2 mL; from day 7 to day 9, the mice of each group were gavaged with 0.2mL of 10% charcoal ice water every day, except for the normal group.
3. Calculation of first-particle stool time and small intestine propulsion rate
After the gavage is completed on day 9, all mice are fasted and are not forbidden to be watered for 24 hours, all mice are gavaged with 0.2mL of 10% activated carbon ice water on day 10, then each group of mice is divided into two groups, and the time for discharging the first black excrement of 5 mice is observed from the start of the gavage of the activated carbon ice water; the remaining 5 mice were sacrificed after 30min in the gavage activated carbon ice water and plasma was collected for future use, the small intestine portion from the pylorus, down to the ileocecal portion was taken, the length of the small intestine and the advancing distance of activated carbon in the small intestine were measured, and the small intestine advancing rate was calculated according to equation (3).
The first black stool time is an important index for evaluating the severity of constipation, and when constipation symptoms occur, the intestinal peristalsis is slowed down, and the retention time of the feces in the intestinal tract is prolonged. The first black stool time of each group of mice is shown in fig. 5, and the first black stool time of the model group of mice is the longest and is significantly higher than that of the normal group of mice (p < 0.05); after the U-FSM, the LB-FSM and the LP-CQPC02-FSM are respectively gavaged, although the first-grain black stool time of the mice is higher than that of a normal group, the mice have significant difference compared with a model group (p is less than 0.05); the first black stool time of LP-CQPC02-FSM gavage mice was significantly lower (p <0.05) than the other two soymilk (U-FSM and LB-FSM).
The influence of the soymilk on the intestinal propulsion rate of the mice with constipation induced by the activated carbon is shown in table 4, and the lengths of the small intestines of the mice in each group have no significant difference, which indicates that the molding of the activated carbon does not influence the length of the small intestine; the rate of intestinal transit was lowest in the model group mice, significantly lower than in the normal group (p < 0.05); after the mice with constipation are subjected to gastric lavage by U-FSM, LB-FSM and LP-CQPC02-FSM, the intestinal propulsion rate is remarkably improved (p is less than 0.05) compared with that of a model group, wherein the intestinal propulsion rate of the LP-CQPC02-FSM group is closest to that of a normal group, which shows that the LP-CQPC02-FSM can promote intestinal peristalsis, accelerate the propelling speed of activated carbon in the intestines and reduce the retention time of the activated carbon in the intestines, so that the constipation is improved to a certain extent.
TABLE 4 influence of soymilk on the intestinal motility of mice with constipation induced by activated carbon
a-eIndicating that there is a significant difference (p) between the groups<0.05)。
4. Observation of small intestine histopathology section
Taking mouse small intestine tissue of about 0.5cm, immediately placing the mouse small intestine tissue in 10% formalin solution for fixation for 48h, dehydrating, transparentizing, waxing, embedding, slicing, performing HE staining, and observing the morphological change of the tissue under an optical microscope.
When the villi of the small intestine are damaged, the peristalsis function of the intestine is influenced to different degrees, and the slow peristalsis of the intestine is one of factors causing constipation, so the integrity of the villi of the small intestine has significance for evaluating the constipation. As shown in FIG. 6, the histopathological section observation of the small intestine of each group of mice shows that the small intestine villi of the normal group of mice are arranged regularly and uniformly, and the phenomena of fracture or shrinkage do not exist, while the small intestine villi of the model group of mice are seriously fractured and shrunk, and the goblet cells are incomplete; although the intestinal villi of the LP-CQPC02-FSM group and the U-FSM group and the LB-FSM group are also shrunk and broken to some extent, the intestinal villi are obviously more complete than those of the model group mice, and the intestinal villi of the LP-CQPC02-FSM group mice are almost consistent with those of the normal group mice.
5. Determination of MTL, Gas, ET, SS, AChE, SP and VIP levels in serum
Mouse plasma was collected and centrifuged at 4000r/min at 4 ℃ for 10min, and the supernatant was collected and their levels in serum were determined separately and exactly according to the kit instructions for MTL, Gas, ET, SS, AChE, SP and VIP.
The measurement results of the serum MTL, Gas, ET, SS, AChE, SP and VIP levels of each group of mice are shown in the table 5, and compared with the other four groups, the serum MTL, Gas, ET, AChE, SP and VIP levels of the mice in the normal group are the highest, and the SS level is the lowest; the model group showed the opposite trend, with highest SS levels in serum and lowest MTL, Gas, ET, AChE, SP and VIP levels; compared with the model group, the serum levels of MTL, Gas, ET, AChE, SP and VIP in mice of the LP-CQPC02-FSM group are obviously improved (p <0.05), and the SS level is obviously reduced (p < 0.05).
TABLE 5 mouse serum MTL, Gas, ET, SS, AChE, SP and VIP levels (pg/mL)
a-eIndicating that there is a significant difference (p) between the groups<0.05)。
Some constipation patients have been reported to have altered neurotransmitter levels (e.g., MTL, Gas, ET, SS, AChE, SP, and VIP). MTL is an important index for evaluating gastrointestinal motility in recent years, and most scholars consider that MTL can promote movement of various parts of the gastrointestinal tract, and the decrease of MTL release can reduce gastrointestinal motility. Gas is an important gastrointestinal hormone which can promote gastric secretion, increase gastrointestinal motility, accelerate gastric emptying and simultaneously promote pyloric sphincter relaxation. ET is a multifunctional peptide that plays an important role in cardiovascular and intestinal function. Ach (acetylcholine) is currently considered as one of two neurotransmitters playing an important role in intestinal motility, and plays a role in promoting gastrointestinal motility by binding to its receptor. In general, AChE levels are positively correlated with Ach levels. SP is an excitatory transmitter of gastrointestinal motor neurons. It strongly promotes contraction of smooth muscles of the digestive tract, stimulates secretion of water and electrolytes from the mucous membranes of the small intestine and colon, and promotes gastrointestinal motility. VIP stimulates intestinal motility, thereby promoting gastrointestinal motility. The above experimental results show that the levels of MTL, Gas, ET, AChE, SP and VIP in the serum of the model group mice are significantly lower than those of the normal group, while the LP-CQPC02-FSM group can significantly increase the levels of these neurotransmitters, indicating that constipation occurs in association with the decrease in the levels of MTL, Gas, ET, AChE, SP and VIP, and the LP-CQPC02-FSM can increase the levels of these neurotransmitters and play a role in relieving constipation.
SS inhibits the release of gastrointestinal hormones, and also reduces the rate of gastric emptying and smooth muscle contraction, all of which can lead to constipation. The above experimental results show that the model group has the highest SS level, and the LP-CQPC02-FSM group has significantly reduced SS level (p <0.05), which means that LP-CQPC02-FSM has certain improvement effect on constipation.
6. Measurement of C-Kit, SCF, TRPV1, GDNF, AQP3 and AQP9mRNA expression levels in the Small intestine
Extracted according to the instructions of Trizol (Invitrogen Co.)Total RNA in the small intestine was purified and concentrated using a ultramicro-spectrophotometer, and the RNA concentration in each sample was adjusted to the same level (1. mu.g/. mu.L). Then 1. mu.L of 1. mu.g/. mu.L RNA sample was taken, 1. mu.L (oligo) primer dT and 10. mu.L sterile ultrapure water were added, mixed, reacted at 65 ℃ for 5min, further added with 1. mu.L Riblolock RNase Inhibitor, 2. mu.L 100mM dNTP mix, 4. mu.L 5 × Reaction buffer and 1. mu.L reverse Aid M-mu/v RT, mixed well, and cDNA was synthesized at 42 ℃, 60min and 70 ℃ for 5 min. The target gene was then reverse transcribed and amplified (see Table 6 for primer sequences). The reaction conditions are as follows: denaturation at 95 ℃ for 15min, annealing at 60 ℃ for 1h, extension at 95 ℃ for 15min, for a total of 40 cycles. GAPDH as housekeeping gene, by 2-ΔΔCTCalculating the relative expression amount of the target gene.
TABLE 6 primer sequences
The expression levels of c-Kit and SCF mRNA in the small intestine of each group of mice are shown in FIG. 7, the expression levels of c-Kit and SCF mRNA in the small intestine of normal group of mice are strongest, the expression levels of c-Kit and SCF in the opposite model group are weakest, the expression levels of c-Kit and SCF in the small intestine of mice can be up-regulated by soybean milk treatment, and the expression levels of c-Kit and SCF in the small intestine of LP-CQPC02-FSM are stronger than those in LB-FSM and U-FSM.
Cajal Cell (ICC) is a special mesenchymal cell, and researches show that the colon movement speed is slowed due to the quantity of the colon ICC, the change of cell morphology and the abnormal cell network structure, and further slow transit constipation can be caused. C-Kit is one of the ICC specific markers, SCF is a natural ligand for the C-Kit receptor. The ICC density in the small intestine of constipation sufferers was found to decrease and indicates that the decrease in ICC is associated with down-regulation of c-Kit gene expression and decreased expression of c-Kit protein and mRNA in the sigmoid colon. The results of the above experiments show that the c-Kit and SCF protein expression and mRNA expression are significantly increased in the small intestine of the mice of LP-CQPC02-FSM group (p <0.05), indicating that LP-CQPC02-FSM treatment can increase the ICC number of constipation mice.
The expression levels of TRPV1 and GDNF mRNA in small intestines of mice in each group are shown in FIG. 8, the GDNF expression intensity of the small intestines of mice in the normal group is strongest, and the expression of TRPV1 is weakest; after constipation induction, GDNF expression of small intestine of the model group mice is reduced, and TRPV1 expression is enhanced; LP-CQPC02-FSM, LB-FSM and U-FSM were all able to up-regulate GDNF expression and down-regulate TRPV1 expression in the constipation mouse small intestine, and LP-CQPC02-FSM was more able to up-and down-regulate than LB-FSM and U-FSM.
TRPV1 is closely associated with defecation and activation of TRPV1 can trigger neurotransmitter release, leading to intestinal dyskinesia. An increase in TRPV1 expression is an important manifestation of intestinal injury, and intestinal injury caused by gastrointestinal diseases can lead to an increase in TRPV1 expression in constipation patients. GDNF can regulate the function of ganglion cells, help repair damaged intestines and improve constipation. Constipation is associated with the enteric nervous system, resulting in muscle tension and impaired gastrointestinal motility. Modulation of the expression levels of TRPV1 and GDNF is one of the important mechanisms for relieving constipation.
The expression levels of AQP3 and AQP9mRNA in small intestines of mice in each group are shown in FIG. 9, the expression of AQP3 in the small intestines of mice in a normal group is the weakest, and the expression of AQP9 is the strongest; after constipation induction, the expression of AQP9 in the small intestine of the model group mice is reduced, and the expression of AQP3 is enhanced; LP-CQPC02-FSM, LB-FSM and U-FSM can up-regulate AQP9 expression and down-regulate AQP3 expression of constipation mouse small intestine, and LP-CQPC02-FSM has stronger up-regulation and down-regulation capability than LB-FSM and U-FSM.
AQP3 can promote the colon to excessively absorb water in the intestine, so that the colon mucosa can absorb a large amount of water in the intestine, and the intestinal tract is dried, thereby causing constipation. And AQP9 can promote secretion of colon mucus, keep intestinal mucosa lubricated, facilitate excretion of feces, and relieve constipation.
Finally, it is noted that the above-mentioned embodiments illustrate rather than limit the invention, and that, while the invention has been described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Sequence listing
<110> Chongqing second college of education
<120> Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation
<160>17
<170>SIPOSequenceListing 1.0
<210>1
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
agagtttgat cctggctcag 20
<210>2
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
ctacggctac cttgttacga 20
<210>3
<211>1421
<212>DNA
<213> Lactobacillus plantarum CQPC02(Lactobacillus plantarum CQPC02)
<400>3
ttaggcggtg gttctaaagg ttacccaccg actttgggtg ttaaaactct catggtgtga 60
cgggcggtgt gtacaaggcc cgggaacgta ttcaccgcgg catgctgatc cgcgattact 120
agcgattccg acttcatgta ggcgagttgc agcctacaat ccgaactgag aatggcttta 180
agagattagc ttactctcgc gagttcgcaa ctcgttgtac catccattgt agcacgtgtg 240
tagcccaggt cataaggggc atgatgattt gacgtcatcc ccaccttcct ccggtttgtc 300
accggcagtc tcaccagagt gcccaactta atgctggcaa ctgataataa gggttgcgct 360
cgttgcggga cttaacccaa catctcacga cacgagctga cgacaaccat gcaccacctg 420
tatccatgtc cccgaaggga acgtctaatc tcttagattt gcatagtatg tcaagacctg 480
gtaaggttct tcgcgtagct tcgaattaaa ccacatgctc caccgcttgt gcgggccccc 540
gtcaattcct ttgagtttca gccttgcggc cgtactcccc aggcggaatg cttaatgcgt 600
tagctgcagc actgaagggc ggaaaccctc caacacttag cattcatcgt ttacggtatg 660
gactaccagg gtatctaatc ctgtttgcta cccatacttt cgagcctcag cgtcagttac 720
agaccagaca gccgccttcg ccactggtgt tcttccatat atctacgcat ttcaccgcta 780
cacatggagt tccactgtcc tcttctgcac tcaagtttcc cagtttccga tgcacttctt 840
cggttgagcc gaaggctttc acatcagact taaaaaaccg cctgcgctcg ctttacgccc 900
aataaatccg gacaacgctt gccacctacg tattaccgcg gctgctggca cgtagttagc 960
cgtggctttc tggttaaata ccgtcaatac ctgaacagtt actctcagat atgttcttct 1020
ttaacaacag agttttacga gccgaaaccc ttcttcactc acgcggcgtt gctccatcag 1080
actttcgtcc attgtggaag attccctact gctgcctccc gtaggagttt gggccgtgtc 1140
tcagtcccaa tgtggccgat taccctctca ggtcggctac gtatcattgc catggtgagc 1200
cgttacccca ccatctagct aatacgccgc gggaccatcc aaaagtgata gccgaagcca 1260
tctttcaaac tcggaccatg cggtccaagt tgttatgcgg tattagcatc tgtttccagg 1320
tgttatcccc cgcttctggg caggtttccc acgtgttact caccagttcg ccactcactc 1380
aaatgtaaat catgatgcaa gcaccaatca ataccagagt c 1421
<210>4
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
catagcccag gtaaagcaca at 22
<210>5
<211>23
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
gaacactcca gaatcgtcaa ctc 23
<210>6
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>6
tcagggacta cgctgcgaaa g 21
<210>7
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>7
aagagctggc agaccgactc a 21
<210>8
<211>19
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>8
ccggcttttt gggaagggt 19
<210>9
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>9
gagacaggta ggtccatcca c 21
<210>10
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>10
ggggtatgga gaagttggct ag 22
<210>11
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>11
ctatgagaat gctgccgaaa a 21
<210>12
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>12
cctctggaca cttggatatg at 22
<210>13
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>13
<210>14
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>14
ctcctgatta ttgtcattgc 20
<210>15
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>15
<210>16
<211>19
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>16
tgcaccacca actgcttag 19
<210>17
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>17
Claims (7)
1. Lactobacillus plantarum (Lactobacillus plantarum) CQPC02 with the preservation number of CGMCC NO. 14491.
2. Use of lactobacillus plantarum CQPC02 according to claim 1 for the preparation of a food product for improving constipation.
3. Use of lactobacillus plantarum CQPC02 in the preparation of a food product for improving constipation according to claim 2, wherein the food product is a fermented beverage.
4. Use of lactobacillus plantarum CQPC02 in the preparation of a food product for improving constipation according to claim 3, wherein the food product is fermented soymilk.
5. A beverage prepared by fermenting Lactobacillus plantarum CQPC02 defined in claim 1.
6. The beverage prepared by fermentation of lactobacillus plantarum CQPC02 according to claim 5, wherein the beverage is soy milk.
7. A method for preparing soybean milk by fermenting lactobacillus plantarum CQPC02 according to claim 1, comprising the steps of: soaking soybean in water 3 times of the soybean for 12 hr, grinding, filtering, and concentrating to 10%5CFU/mL inoculated with Lactobacillus plantarum CQPC02, fermented at 37 ℃ for 12 hours.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810751933.2A CN110699271B (en) | 2018-07-10 | 2018-07-10 | Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810751933.2A CN110699271B (en) | 2018-07-10 | 2018-07-10 | Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110699271A true CN110699271A (en) | 2020-01-17 |
CN110699271B CN110699271B (en) | 2022-11-01 |
Family
ID=69192393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810751933.2A Active CN110699271B (en) | 2018-07-10 | 2018-07-10 | Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110699271B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114774302A (en) * | 2022-03-09 | 2022-07-22 | 重庆第二师范学院 | Lactobacillus plantarum CQPC02, and separation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104381440A (en) * | 2014-07-17 | 2015-03-04 | 西南民族大学 | Lactobacillus fermentum Lee working fermenting agent product and application thereof to prevent constipation and keep healthy |
CN104498383A (en) * | 2014-05-28 | 2015-04-08 | 西南大学 | Lactobacillus fermentum strain suo for adjusting intestinal tract motion and preventing constipation and use thereof |
CN106417621A (en) * | 2016-09-21 | 2017-02-22 | 徐州工程学院 | Sour soybean milk and preparation technology thereof |
CN107099491A (en) * | 2017-07-05 | 2017-08-29 | 重庆第二师范学院 | Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared |
CN107099492A (en) * | 2017-07-05 | 2017-08-29 | 重庆第二师范学院 | Lactobacillus plantarum YS4 and its application in the food of Constipation is prepared |
CN107307086A (en) * | 2017-06-08 | 2017-11-03 | 青岛科海生物有限公司 | A kind of application process of β glucuroides in soymilk |
-
2018
- 2018-07-10 CN CN201810751933.2A patent/CN110699271B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104498383A (en) * | 2014-05-28 | 2015-04-08 | 西南大学 | Lactobacillus fermentum strain suo for adjusting intestinal tract motion and preventing constipation and use thereof |
CN104381440A (en) * | 2014-07-17 | 2015-03-04 | 西南民族大学 | Lactobacillus fermentum Lee working fermenting agent product and application thereof to prevent constipation and keep healthy |
CN106417621A (en) * | 2016-09-21 | 2017-02-22 | 徐州工程学院 | Sour soybean milk and preparation technology thereof |
CN107307086A (en) * | 2017-06-08 | 2017-11-03 | 青岛科海生物有限公司 | A kind of application process of β glucuroides in soymilk |
CN107099491A (en) * | 2017-07-05 | 2017-08-29 | 重庆第二师范学院 | Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared |
CN107099492A (en) * | 2017-07-05 | 2017-08-29 | 重庆第二师范学院 | Lactobacillus plantarum YS4 and its application in the food of Constipation is prepared |
Non-Patent Citations (3)
Title |
---|
LI CHUAN: "Effect of Lactobacillus plantarum NCU116 on loperamide-induced constipation in mice.", 《INT J FOOD SCI NUTR》 * |
YI RUOKUN等: "Lactobacillus plantarum CQPC02-Fermented Soybean Milk Improves Loperamide-Induced Constipation in Mice.", 《J MED FOOD》 * |
易若琨等: "植物乳杆菌YS-1对活性炭诱导小鼠便秘的预防作用", 《食品科学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114774302A (en) * | 2022-03-09 | 2022-07-22 | 重庆第二师范学院 | Lactobacillus plantarum CQPC02, and separation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN110699271B (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111117907B (en) | Lactobacillus paracasei CCFM1069 and application thereof | |
CN109628346B (en) | Lactobacillus fermentum CQPC04 and application thereof in preparing fermented food | |
CN105132318B (en) | Lactobacillus plantarum Grx16 and its application | |
CN109619184B (en) | Application of lactobacillus plantarum CQPC02 in preparation of medicine for preventing oxidative damage of liver | |
CN110305820B (en) | Lactobacillus rhamnosus CCFM1064 and application thereof | |
CN114634901B (en) | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof | |
CN107099492B (en) | Lactobacillus plantarum YS4 and application thereof in preparation of constipation preventing food | |
CN111073834B (en) | Bifidobacterium longum subspecies longum CCFM1102 and application thereof | |
CN116790448B (en) | Lactobacillus helveticus OPB102 capable of relieving constipation and diarrhea and application thereof | |
CN106906165B (en) | Lactobacillus plantarum and application thereof in preparation of food for preventing constipation | |
CN111197018A (en) | Lactobacillus acidophilus, method for fermenting soybean milk by using lactobacillus acidophilus, prepared fermented soybean milk and application | |
CN110699271B (en) | Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation | |
CN109645490A (en) | Application of the lactobacillus plantarum CQPC02 in the food or drug of preparation prevention diabetes | |
CN110692726A (en) | Lactobacillus plantarum CQPC01 and application thereof in preparation of food for improving constipation | |
CN109362882B (en) | Lactobacillus fermentum CQPC07 and application thereof in preparing food or medicine for improving ulcerative colitis | |
CN109385387B (en) | TGEV-resistant lactobacillus reuteri and application thereof | |
CN116286519B (en) | Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines | |
CN115895973B (en) | Lactobacillus paracasei and application thereof in fermentation preparation of white sour soup | |
CN107099491A (en) | Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared | |
CN115011515B (en) | Strain for increasing plant alcohol content in alfalfa silage and application thereof | |
CN112877260B (en) | Lactobacillus paracasei for relieving purgative colon and application thereof | |
CN109619183B (en) | Application of lactobacillus plantarum CQPC03 in preparation of medicine for preventing oxidative damage of liver | |
CN113308419B (en) | Lactobacillus chaff for fermentation and application thereof | |
CN115992071A (en) | Lactobacillus plantarum CCFM1280 with athletic fatigue relieving function and application thereof | |
CN109609409A (en) | Lactobacillus fermenti CQPC06 and its application in the food or drug that preparation improves ulcerative colitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221019 Address after: 215300 Sanjia Road 388, Zhangpu Town, Kunshan City, Suzhou City, Jiangsu Province Applicant after: THANKCOME BIOTECHNOLOGY (SUZHOU) CO.,LTD. Address before: No.9, Xuefu Avenue, Nan'an District, Chongqing, 400067 Applicant before: CHONGQING University OF EDUCATION |